Linagliptin tablet

DRUG3 trials

Sponsors

Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Hospital Regional de Alta Especialidad del Bajio

Conditions

Covid19HealthyHyperglycemiaType 2 Diabetes Mellitus

Phase 1

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

CompletedNCT02183636

Boehringer IngelheimHealthy

Start: 2009-08-31Updated: 2014-07-08

Phase 2

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Type 2 Diabetes Mellitus

Start: 2020-01-01End: 2020-09-30Target: 120Updated: 2020-03-13

Phase 3

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

CompletedNCT04542213

Hospital Regional de Alta Especialidad del BajioCovid19, Hyperglycemia

Start: 2020-08-01End: 2021-02-28Updated: 2021-03-23

Related Papers

Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection.

2022-01-1113 citations